Skip to content

Pharma Universalis

Active Private limited companyfounded 2024active for 2 yearsKerkweg 20, 3020 HerentKBO/BCE: BE 1004.253.371

Annual accounts 2025

micro format, filed on 28-05-2026, 64 days before the deadline
€59,622
▲ 4.0%
€58,190
▲ 5.6%
€45,822
▲ 5.1%
€90,109
▲ 110%
73.1%
▲ 4.9 percentage points
3.64
▲ 0.69

Turnover is estimated at about €120,000, probably between €97,000 and €170,000. The micro format does not state turnover.

Balance sheet

balance sheet total €129,198 on 31-12-2025
What the company ownsHow it is paid for

in euro

in euro

Position in the sector

73.1%

Higher than 72% of the 10,299 companies filing micro accounts in office administrative support (NACE 82) in 2025.

3.64

Higher than 72% of the 9,879 companies filing micro accounts in office administrative support (NACE 82) in 2025.

35.5%

Higher than 80% of the 10,021 companies filing micro accounts in office administrative support (NACE 82) in 2025.

Pharma Universalis Middle half of the sector 80% of the sector Micro accounts in office administrative support (NACE 82)

Net result: middle half · Equity: middle half · Balance sheet total: middle half · Working capital: middle half

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend20252024
59,62257,214
47,25445,685
946,693
58,918-
90,10942,910
73.1%68.1%
3.642.95
0.370.47
48.5%89.7%
35.5%61.1%
over 100over 100

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend20252024
Balance sheet: assets
20/58 129,19871,306
20 094
21/28 4,9886,327
22/27 4,9886,327
24 4,9886,327
29/58 124,20964,886
40/41 10,13512,100
40 10,13512,100
54/58 111,70452,786
490/1 2,370-
Balance sheet: equity and liabilities
10/49 129,19871,306
10/15 94,40348,581
10/11 5,0005,000
13 89,40343,581
133 89,40343,581
17/49 34,79522,725
42/48 34,10021,976
44 3968
440/4 3968
45 33,67421,654
450/3 30,59418,590
454/9 3,0803,064
47/48 386254
492/3 695749
Income statement
9900 59,62257,319
630 1,4322,104
640/8 0106
9901 58,19055,110
65/66B 10130
65 10130
9903 58,08855,080
67/77 12,26711,499
9904 45,82243,581
9905 45,82243,581
Appropriation of the result
9906 45,82243,581
691/2 45,82243,581
6921 45,82243,581
Document PDFPDF

The full notes are in the filed accounts (PDF).

Source: Annual accounts 2025 (PDF), filed on 28-05-2026.

Filings

each dot is a set of accounts, on the day it reached the National Bank
Financial year Type Filed Reference Document
31-12-2025 micro format 28-05-2026 2026-00124666 PDF
31-12-2024 micro format 09-07-2025 2025-00249883 PDF

Investments

fixed assets acquired
Item20252024
Tangible fixed assets-€6,693
€1,432€2,104

Source: notes to the 2024 to 2025 annual accounts (statement of fixed assets)

Insights on Pharma Universalis

The operating result for 2025 is 6% higher than in 2024.

Debt's share of the balance-sheet total falls from 31.9% to 26.9%. Equity and debt are higher.

Next steps